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Abstract
OBJECTIVE: The accumulation of extracellular ma-
trix (ECM) is one of the main causes of renal fibro-
sis. Emerging evidence suggests that the metabolic
enzyme of ECM is associated with renal fibrosis. In
this study, we applied randomly controlled trial to
check the curative effect of Chinese herbs on pa-
tients with immunoglobulin A nephropathy (IgAN).
METHODS: Twenty-six patients were randomly di-
vided into group A (control group) treated with
Western Medicine and group B (treatment group)
treated with combination of Traditional Chinese
Medicine (TCM) and Western Medicine. Blood and
urine tests were done before treatment and after
8-week treatment.
RESULTS: The levels of the main composition of ex-
tracellular matrix (MC-ECM), the metabolic enzyme
of ECM (ME-ECM) and some cytokines in group B
decreased more obviously than those in group A af-
ter 8-week treatment. So did the level of 24-hour
urine protein. However, Metal matrix protease
(MMP)-2 and vascular endothelial growth factor in
group B increased more obviously than those in
group A after 8-week treatment. No effects on the
renal function were found in both groups.
CONCLUSION: Our study provided important infor-
mation on using the combination of TCM with
Western Medicine to inhibit the progression of re-
nal fibrosis in patients with IgAN.
© 2013 JTCM. All rights reserved.
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INTRODUCTION
Chronic kidney disease (CKD) has gradually become
an emerging health problem worldwide with aging
populations continuously growing. According to the di-
agnostic criteria formulated by National Kidney Foun-
dation Kidney Disease Outcomes Quality Initiative
(KDOQI), primary chronic nephritis mostly develop
into CKD1 Through out the world, 10%-20% of pri-
mary chronic nephritis is immunoglobulin A nephropa-
thy (IgAN) and, of them, more than 40% in Asia.2-4
More and more renal failure patients, underwent costly
renal replacement therapy, experienced poor out-
comes.5-6 Therefore, an effective cure should be sought
for IgAN.7 Excessive accumulation of ECM virtually
existing in any type of CKD inevitably results in renal
fibrosis and ultimately leads to end-stage kidney dis-
ease (ESRD). In order to prevent CKD from becoming
ESRD,8 it is urgently necessary to diagnose and treat it
at early stage. In recent years, substantial studies have
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been conducted to reveal the underlying mechanism of
renal fibrosis. There is increasing evidence that intra-re-
nal cytokines including chemokines, inflammatory me-
diators and growth factors are involved in the initiation
and progression of renal fibrosis. The most important
cytokine is transforming growth factor β1 (TGF-β1).9-10
It is the key promoter in the process of tissue fibrosis.
In recent studies, vascular endothelial growth factor
(VEGF) has been confirmed to be able to prevent renal
filtration.11 This finding provided the basis for develop-
ing new diagnosis and treatment strategies to forestall
the progression of CKD. Previous studies documented
that blood and urinary cytokines excretion was associat-
ed with the initiation, progression of various kidney
diseases and with their outcomes. Some studies also
demonstrated that urinary excretion of TGF-β1 might
be a sensitive indicator to the activity of kidney diseas-
es.12-14 Other investigators reported that matrix metallo-
peptidase 2 (MMP-2) and tissue inhibitor of metallo-
proteinase 1 (TIMP-1) were related to the progression
of kidney diseases.15-16 These studies indicated that
TGF-β1, VEGF, main composition of extracellular ma-
trix (MC-ECM) and metabolic enzyme of ECM
(ME-ECM) in both blood and urine might be useful
biomarkers showing the progression of renal fibrosis.
As known to all, perturbations to the normal state of
physiological system will clinically invoke a complex re-
sponse (not a single factor). In this study, we used dif-
ferent methods to treat patients with IgAN and ana-
lyzed the change in TGF-β1, ME-ECM and
MC-ECM by means of enzyme-lnked immunosor-
bent assay (ELISA).
MATERIALS ANDMETHODS
Patient selection
The study was approved by the Animal Ethnics Com-
mittee of the First Hospital Affiliated to Soochow Uni-
versity. All the participants signed informed consent.
In this study, 26 IgAN patients were diagnosed with re-
nal biopsy as CKD at stage 1-3 according to the K/
DOQI guideline.1 Other kinds of CKD or the renal
function at stage 4-5 were exclued. The general clinical
features of the 26 patients before treatment are listed in
table 1. These patients were randomly divided into two
groups: group A, 8 males and 5 females, was treated
with Western Medicine (WM)[average creatinine clear-
ance rate (Ccr): (109±22) mL/min per 1.73 m2]; group
B, 8 males and 5 females, with TCM plus WM [aver-
age Ccr: (107±30) mL/min per 1.73 m2].
The patients in 2 groups were treated with prednisone
(1 mg·d-1·kg-1 per 1.73 m2 body surface area) QD, if
total urinary protein at 24 h (TUP)>1.0 g. Those with
high blood lipid, hypertension or edema were adminis-
tered aid medications such as Lotensin® (Novartis, Bei-
jing, China). The patients in groups B were treated
with WM and modified Dangguibuxue Tang, a TCM
decoction. Its one dose was orally administered twice a
day for 8 weeks as a course of treatment. Its recipe con-
sisted of Radix Astragali 30 g, Radix Angelicae Sinensis
6 g, Radix Acanthopanacis Bidentatae 15 g, Cortex Eu-
commiae 6 g, Rhizoma Dioscoreae 20 g, Rhizoma Ch-
uanxiong 15 g and Hedyotic diffusa 30 g. Flos Carthami
10 g and Semen Persicae 10 g are added for blood stasis,
Cortex Cinnamomi 3 g and Radix Pseudostellariae 10 g
for deficiency of kidney-Qi, and Rhizoma Coptidis 6 g
and Radix Aucklandiae 10 g for damp heat in middle
energizer. All the Chinese herbs were purchased from
Suzhou Tianling Pharmaceutical Co. Ltd. China.
Sample collection
The samples of fasting venous blood and min-stream
urine were taken in the morning before treatment and
the same samples done after 8 weeks treatment.
Samples were centrifuged immediately for 5 min at
2000 rpm to remove cells and debris and stored
at -80℃ for analysis. Sera were stored at -80℃ for no
more than 4 months before measurement. Data of
TUP, serum creatinine (Scr) and Cr clearance (Ccr)
came from the clinical data base. TUP and Scr were
measured in the biochemical laboratory center of the
hospital. Ccr was not measured but calculated with
Cockroft and Gault formula.1
ELISA test
ELISA was used to detect blood and urinary excretion
of TGF-β1, VEGF and other factors such as ME-ECM
and MC-ECM. Briefly, plates were blocked and incu-
bated at room temperature for 2 h, the plates were
washed with buffer for 4-6 times and dried with filter
paper. The samples were added to biotinylated antibod-
ies (100 μL/hole) and incubated for 1 h. at 37℃. Both
procedures must be done twice. The reaction was
stopped with stopping solution (100 μL/hole). Plates
were read with a microplate reader (JETLIA-962 Sys-
tem, Beijing, China) at the wave length of 450 nm.
Data analysis
Data were analyzed with SPSS 15.0 for Windows.
P<0.05 was significant level.
RESULTS
According to the pathological changes in both glomcru-
lus and renal tubule classified by Hass from subclassⅠ
to subclass Ⅴ,17 of the 26 IgAN patients, 7 patients
were of subclassⅠ and the others of subclassⅡ.
As shown in Table 1-4, both the level of TGF-β1,
VEGF, MC-ECM, ME-ECM and the excretion of
TUP and Ccr before treatment showed no significant
difference between group A and group B (P>0.05).
After 8-week treatment, the quantity of TIMP-1,
TGF-β1, MC-ECM and TUP obviously decreased from
their levels before treatment and the quantity of
MMP-2 and VEGF obviously increased compared to
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their levels before treatment (P<0.05). The quantity of
TIMP-1,TGF-β1, MC-ECM and TUP in group B de-
creased more obviously than in group A (P<0.05). The
quantity of MMP-2 and VEGF in group B increased
more obviously than in group A (P<0.05) (Table 1-4).
Ccr remained unchanged in the two groups (P>0.05)
(Table 1).
DISCUSSION
In the study, we proposed a strategy for treating IgAN.
Our data demonstrated that the combination of TCM
with WM could effectively treat IgAN. To our knowl-
edge, this was the first randomized controlled study to
explore the effect of combinating the two medicines on
IgAN in humen. We confirmed the effect of modified
Dangguibuxue Tang on IgAN in both experimental
and clinical researches.18-20
Hyaluronic acid (HA), laminin(LN), collagen(Col)-Ⅳ
and Precollagen III peptide(PⅢNP) are widely used as
the marker of ECM. Recent studies proved that TGF-β1,
MMP-2 and TIMP-1 could affect the accumulation of
the ECM. It is known21-24 to us that the proportion of
ECM in the tissue determined the process of organ fi-
brosis. Therefore, the levels of MC-ECM, ME-ECM
and TGF-β1 could directly or indirectly express the de-
gree of organ fibrosis. VEGF is one of the cytokines
which may protect the filtration barrier and decrease
the breakthrough of urine protein which intimates the
expression of the VEGF. We found that TUP could ob-
viously increase after using the soluble receptor of
VEGF or the anti-VEGF.25,26 Some researchers con-
firmed that the use of anti-VEGF to treat the patients
with malignant tumor and without the history of renal
disease could provoke both nephropathy and hyperten-
sion in clinical practice. These investigations discov-
ered that VEGF influenced the production of urine
protein and renal hypertension.15 Both clinical investi-
gation and empirical study confirmed that VEGF had
both the function of maintaining the renal filtration
barrier at physiological functions and the function of
decreasing the breakthrough of urine protein at patho-
logic state.25-27
Some studies proved that MMPs, the degrading en-
zymes of ECM, rose significantly in IgAN patients.
The activity of MMPs was regulated by several types of
Table 1 TUP and Ccr before and after treatment ( xˉ ± s )
Notes: TUP: total urinary protein at 24 h; Ccr: creatinine
clearance rate. Group A (control group) treated with Western
Medicine. Group B (treatment group) treated withWestern
Medicine and modified Dangguibuxue Tang. P>0.05, bP<0.05,
compared with the datum in the control group,cP>0.05, dP<
0.05, compared with the datum in the same group after 4 or
8-week treatment.
Group
A
B
Time
(week)
0
4
8
0
4
8
n
16
16
16
16
16
16
TUP（g/24 h）
5.2±1.2d
3.7±1.2
2.1±0.9
5.8±1.1ad
3.6±1.1a
1.2±0.7b
Ccr (mL/min)
108.8±21.6c
109.3±22.0
108.8±21.9
106.8±29.5ac
107.5±27.9a
106.9±28.7a
Table 2 Main composition of ECM and metabolic enzyme of ECM in serum ( xˉ ± s )
Group
A
B
Time (week)
0
8
0
8
HA (μg/L)
145.0±14.2d
106.7±12.4
140.2±13.4ad
80.2±11.7b
LN (μg/L)
157.2±14.1d
107.8±12.6
152.7±12.6ad
94.4±13.9b
Col-Ⅳ (μg/L)
153.1±7.9d
118.8±10.7
151.9±9.3ad
97.9±16.8b
PⅢNP (μg/L)
13.2±1.4d
11.4±1.1
13.2±1.6ad
10.1±1.2b
TIMP-1 (μg/L)
516.9±52.9d
458.8±50.4
520.6±53.7ad
382.5±49.7b
MMP-2 (μg/L)
234.4±55.0d
188.3±39.9
225.0±70.6ad
208.1±44.3b
Notes: Group A (control group) treated with Western Medicine; group B (treatment group) treated withWestern Medicine and modified
Dangguibuxue Tang. ECM: extracellular matrix; HA: Hyaluronic acid; LN: laminin; Col-Ⅳ: collagenⅣ; PⅢNP: precollagen III peptide;
TIMP-1: tissue inhibitor of metalloproteinase 1; MMP-2: metal matrix protease 2. aP>0.05, bP<0.05, compared with the datum in the
control group; cP>0.05, dP<0.05, compared with the datum in the same group after 8-week treatment.
Table 3 MC-ECM and ME-ECM in urine ( xˉ ± s )
Group
A
B
Time (week)
0
8
0
8
LN (μg/L)
202.4±31.2d
184.9±17.0
195.9±17.6ad
179.9±13.6a
Col-Ⅳ (mg/L)
8.4±0.8d
7.2±0.53
8.4±0.8ad
7.0±0.5b
TIMP-1 (μg/L)
219.0±8.6d
214.2±8.0
218.6±6.9ad
209.0±7.2b
MMP-2 (μg/L)
524.9±6.7d
543.5±5.1
524.3±5.8ad
551.2±6.0b
Notes: Group A (control group) treated with Western Medicine; group B (treatment group) treated withWestern Medicine and modified
Dangguibuxue Tang. MC-ECM: main composition of extracellular matrix; ME-ECM: metabolic enzyme of extracellular matrix; LN:
laminin; Col-Ⅳ: collagenⅣ; TIMP-1: tissue inhibitor of metalloproteinase 1; MMP-2: metal matrix protease 2. aP>0.05, bP<0.05,
compared with the datum in the control group; cP>0.05, dP<0.05, compared with the datum in the same group after 8-week treatment.
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inhibitors, of which TIMPs were the most important.
In the family of MMPs and TIMPs, MMP-2 and
TIMP-1 were the most important compositions which
expressed themselves in the kidney tissue. MMP/
TIMP imbalance was involved in renal remodeling.28
Urinary MMP-2 and TIMP-1 increased at the early
stage of IgAN. In addition, it was also found that the
levels of TIMP-1 and TGF-β at the early stage of IgAN
were higher than those in control group. We hold that
all of them might reflect the state of micro-inflamma-
tion and serve as the valuable biomarkers for monitor-
ing the progression of IgAN. Cytokines, diverse groups
of soluble proteins secreted by various cells, played an
important role in innate immunity, cell death, angio-
genesis, cell invasion, cell growth and differentiation.
Many studies documented the role of cytokines in dif-
ferent physiological states.
Studies showed that TGF-β1, VEGF, MMP-2 and
TIMP-1 could serve as effective markers of the condi-
tion of renal fibrosis.5, 29-34 The utility of cytokines,
MC-ECM and ME-ECM in predicting or monitoring
IgAN progression was useful to nephrologists. It is a
classic technology that the level of cytokines, MC-
ECM and ME-ECM could be determined by ELISA.
As known to all, none of them could reflect informa-
tion arising from this complex process of initiation and
progression of renal fibrosis. The tests of them un-
doubtedly would provide insights into the condition of
renal disease.
By analyzing the data (Table 1-4), we found that West-
ern Medicine alone and its integrated with TCM could
effectively treat IgAN. However, the combination of
them could more effectually decrease both TUP and
TGF-β1 than the Western Medicine alone. At the same
time, their joint action could effectively affect the level
of MC-ECM and ME-ECM in serum and urine of the
patients with IgAN.
In conclusion, the study demonstrated the feasibility of
the combination of both medicines to treat IgAN. Nev-
ertheless, the method with some limitations is still fac-
ing some challenges. The main obstacles to apply this
treatment are: 1) Some indicator variables used in the
study must be quantified; 2) practitioners must have
clinical experience of TCM. In the future, a study with
a larger sample size is required to further explore fibro-
sis-resisting effect of the joint therapy on the progres-
sion of renal diseases.
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